DNA integrity as biomarker in pancreatic cyst fluid

Wesley Utomo; Vincent Janmaat; Auke Verhaar; J Cros; P Levy; P Ruszniewski; Mirella Berg; Guido Jenster; Marco Bruno; Henri Braat; Gwenny Fuhler; Maikel Peppelenbosch

DNA integrity as biomarker in pancreatic cyst fluid

Wesley Utomo, Vincent Janmaat, Auke Verhaar, J Cros, P Levy, P Ruszniewski, Mirella Berg, Guido Jenster, Marco Bruno, Henri Braat, Gwenny Fuhler, Maikel Peppelenbosch

Research output: Contribution to journal › Article › Academic › peer-review

8 Citations (Scopus)

Abstract

Identification of pancreatic cysts with malignant potential is important to prevent pancreatic cancer development. Integrity of cell free DNA (cfDNA) has been described as tumor biomarker, but its potential for pancreatic cancer is unclear. While normal apoptotic cells release uniformly truncated DNA, malignant tissues release long fragments of cell free DNA (cfDNA). We measured 247 base pair (bp) and 115 bp DNA fragments of ALU repeats by qPCR in serum from healthy controls and pancreatic cancer patients, and in cyst fluid from pancreatic cyst patients. No differences in total cfDNA (ALU115) and cfDNA integrity (ALU247/115) were observed between sera from healthy controls (n=19) and pancreatic cancer patients (n=19). Although elevated as compared to serum, but no differences in cfDNA were found in cyst fluid from high risk (n=10) and low risk (n=20) cyst patients. We conclude that cfDNA integrity is not a useful marker to identify (pre) malignant pancreatic lesions.

Original language	Undefined/Unknown
Pages (from-to)	1837-1841
Number of pages	5
Journal	American Journal of Cancer Research
Volume	6
Issue number	8
Publication status	Published - 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{95d02a9606a247939c717f693d6e8678,

title = "DNA integrity as biomarker in pancreatic cyst fluid",

abstract = "Identification of pancreatic cysts with malignant potential is important to prevent pancreatic cancer development. Integrity of cell free DNA (cfDNA) has been described as tumor biomarker, but its potential for pancreatic cancer is unclear. While normal apoptotic cells release uniformly truncated DNA, malignant tissues release long fragments of cell free DNA (cfDNA). We measured 247 base pair (bp) and 115 bp DNA fragments of ALU repeats by qPCR in serum from healthy controls and pancreatic cancer patients, and in cyst fluid from pancreatic cyst patients. No differences in total cfDNA (ALU115) and cfDNA integrity (ALU247/115) were observed between sera from healthy controls (n=19) and pancreatic cancer patients (n=19). Although elevated as compared to serum, but no differences in cfDNA were found in cyst fluid from high risk (n=10) and low risk (n=20) cyst patients. We conclude that cfDNA integrity is not a useful marker to identify (pre) malignant pancreatic lesions.",

author = "Wesley Utomo and Vincent Janmaat and Auke Verhaar and J Cros and P Levy and P Ruszniewski and Mirella Berg and Guido Jenster and Marco Bruno and Henri Braat and Gwenny Fuhler and Maikel Peppelenbosch",

year = "2016",

language = "Undefined/Unknown",

volume = "6",

pages = "1837--1841",

number = "8",

}

TY - JOUR

T1 - DNA integrity as biomarker in pancreatic cyst fluid

AU - Utomo, Wesley

AU - Janmaat, Vincent

AU - Verhaar, Auke

AU - Cros, J

AU - Levy, P

AU - Ruszniewski, P

AU - Berg, Mirella

AU - Jenster, Guido

AU - Bruno, Marco

AU - Braat, Henri

AU - Fuhler, Gwenny

AU - Peppelenbosch, Maikel

PY - 2016

Y1 - 2016

N2 - Identification of pancreatic cysts with malignant potential is important to prevent pancreatic cancer development. Integrity of cell free DNA (cfDNA) has been described as tumor biomarker, but its potential for pancreatic cancer is unclear. While normal apoptotic cells release uniformly truncated DNA, malignant tissues release long fragments of cell free DNA (cfDNA). We measured 247 base pair (bp) and 115 bp DNA fragments of ALU repeats by qPCR in serum from healthy controls and pancreatic cancer patients, and in cyst fluid from pancreatic cyst patients. No differences in total cfDNA (ALU115) and cfDNA integrity (ALU247/115) were observed between sera from healthy controls (n=19) and pancreatic cancer patients (n=19). Although elevated as compared to serum, but no differences in cfDNA were found in cyst fluid from high risk (n=10) and low risk (n=20) cyst patients. We conclude that cfDNA integrity is not a useful marker to identify (pre) malignant pancreatic lesions.

AB - Identification of pancreatic cysts with malignant potential is important to prevent pancreatic cancer development. Integrity of cell free DNA (cfDNA) has been described as tumor biomarker, but its potential for pancreatic cancer is unclear. While normal apoptotic cells release uniformly truncated DNA, malignant tissues release long fragments of cell free DNA (cfDNA). We measured 247 base pair (bp) and 115 bp DNA fragments of ALU repeats by qPCR in serum from healthy controls and pancreatic cancer patients, and in cyst fluid from pancreatic cyst patients. No differences in total cfDNA (ALU115) and cfDNA integrity (ALU247/115) were observed between sera from healthy controls (n=19) and pancreatic cancer patients (n=19). Although elevated as compared to serum, but no differences in cfDNA were found in cyst fluid from high risk (n=10) and low risk (n=20) cyst patients. We conclude that cfDNA integrity is not a useful marker to identify (pre) malignant pancreatic lesions.

M3 - Article

SN - 2156-6976

VL - 6

SP - 1837

EP - 1841

JO - American Journal of Cancer Research

JF - American Journal of Cancer Research

IS - 8

ER -